CH650514A5 - Verfahren zur herstellung von 5'-desoxy-5'-methylthioadenosin. - Google Patents
Verfahren zur herstellung von 5'-desoxy-5'-methylthioadenosin. Download PDFInfo
- Publication number
- CH650514A5 CH650514A5 CH4716/84A CH471684A CH650514A5 CH 650514 A5 CH650514 A5 CH 650514A5 CH 4716/84 A CH4716/84 A CH 4716/84A CH 471684 A CH471684 A CH 471684A CH 650514 A5 CH650514 A5 CH 650514A5
- Authority
- CH
- Switzerland
- Prior art keywords
- mta
- agglomeration
- platelet
- tests
- induced
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title description 2
- DKJLSDXXOAIWNM-IOSLPCCCSA-N (2R,3R,4R,5R)-5-(6-aminopurin-9-yl)-2-ethyl-4-sulfanyloxolan-3-ol Chemical compound S[C@@H]1[C@H](O)[C@@H](CC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 DKJLSDXXOAIWNM-IOSLPCCCSA-N 0.000 title 1
- WUUGFSXJNOTRMR-UHFFFAOYSA-N 5alpha-Hydroxy-3abeta,5beta,8-trimethyl-1-(1,5-dimethyl-hexen-(4)-yl)-4abetaH,7abetaH-dicyclopentano[a.d]cyclooctaen-(8) Natural products OC1C(O)C(CSC)OC1N1C2=NC=NC(N)=C2N=C1 WUUGFSXJNOTRMR-UHFFFAOYSA-N 0.000 claims description 53
- 238000000034 method Methods 0.000 claims description 21
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 claims description 4
- 229960001570 ademetionine Drugs 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 3
- 239000002244 precipitate Substances 0.000 claims description 2
- 238000010992 reflux Methods 0.000 claims description 2
- WUUGFSXJNOTRMR-WOIOKPISSA-N 5'-deoxy-5'-methylthioadenosine Chemical compound O[C@@H]1[C@@H](O)[C@H](CSC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 WUUGFSXJNOTRMR-WOIOKPISSA-N 0.000 claims 3
- 239000007864 aqueous solution Substances 0.000 claims 3
- 238000001704 evaporation Methods 0.000 claims 1
- 230000008020 evaporation Effects 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 238000006386 neutralization reaction Methods 0.000 claims 1
- 239000011541 reaction mixture Substances 0.000 claims 1
- WUUGFSXJNOTRMR-IOSLPCCCSA-N 5'-S-methyl-5'-thioadenosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CSC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 WUUGFSXJNOTRMR-IOSLPCCCSA-N 0.000 description 50
- 238000005054 agglomeration Methods 0.000 description 33
- 238000012360 testing method Methods 0.000 description 33
- 230000002776 aggregation Effects 0.000 description 32
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 12
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 12
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 11
- 102000008186 Collagen Human genes 0.000 description 10
- 108010035532 Collagen Proteins 0.000 description 10
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 10
- 229920001436 collagen Polymers 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 230000001681 protective effect Effects 0.000 description 9
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- 230000003110 anti-inflammatory effect Effects 0.000 description 6
- 229960000905 indomethacin Drugs 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 5
- 230000001754 anti-pyretic effect Effects 0.000 description 5
- 229940114079 arachidonic acid Drugs 0.000 description 5
- 235000021342 arachidonic acid Nutrition 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000007062 hydrolysis Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Natural products CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
- 230000000202 analgesic effect Effects 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- RMMXTBMQSGEXHJ-UHFFFAOYSA-N Aminophenazone Chemical compound O=C1C(N(C)C)=C(C)N(C)N1C1=CC=CC=C1 RMMXTBMQSGEXHJ-UHFFFAOYSA-N 0.000 description 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 2
- 235000005979 Citrus limon Nutrition 0.000 description 2
- 244000131522 Citrus pyriformis Species 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 229960005305 adenosine Drugs 0.000 description 2
- 229960000212 aminophenazone Drugs 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000000416 exudates and transudate Anatomy 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- RLQZIECDMISZHS-UHFFFAOYSA-N 2-phenylcyclohexa-2,5-diene-1,4-dione Chemical compound O=C1C=CC(=O)C(C=2C=CC=CC=2)=C1 RLQZIECDMISZHS-UHFFFAOYSA-N 0.000 description 1
- -1 ADP Chemical compound 0.000 description 1
- 240000001624 Espostoa lanata Species 0.000 description 1
- 235000009161 Espostoa lanata Nutrition 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000012496 blank sample Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000008423 pleurisy Diseases 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000002885 thrombogenetic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT21550/80A IT1193529B (it) | 1980-04-22 | 1980-04-22 | Derivati adenosinici ad attivita' antinfiammatoria ed analgesica e composizioni terapeutiche che li contengono come principio attivo |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH650514A5 true CH650514A5 (de) | 1985-07-31 |
Family
ID=11183457
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH4716/84A CH650514A5 (de) | 1980-04-22 | 1981-04-22 | Verfahren zur herstellung von 5'-desoxy-5'-methylthioadenosin. |
| CH263281A CH645544A5 (de) | 1980-04-22 | 1981-04-22 | Therapeutisches, adenosin-derivate mit entzuendungshemmender, analgetischer und antipyretischer wirksamkeit enthaltendes mittel. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH263281A CH645544A5 (de) | 1980-04-22 | 1981-04-22 | Therapeutisches, adenosin-derivate mit entzuendungshemmender, analgetischer und antipyretischer wirksamkeit enthaltendes mittel. |
Country Status (17)
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1177373B (it) * | 1984-12-06 | 1987-08-26 | Bioresearch Spa | Sali della 5'-metiltio-5'-deossiadenosina con acidi solfonici a lunga catena alchilica |
| IT1227049B (it) * | 1988-07-29 | 1991-03-14 | Bioresearch Spa | Impiego di derivati adenosinici per la preparazione di composizioni farmaceutiche aventi attivita' immunostimolante. |
| JPH0497287A (ja) * | 1990-08-10 | 1992-03-30 | Nec Ic Microcomput Syst Ltd | 画像表示集積回路 |
| WO2006097547A1 (es) * | 2005-03-17 | 2006-09-21 | Proyecto De Biomedicina Cima S.L. | Empleo de 5'-metiltioadenosina (mta) en la prevención y/o tratamiento de enfermedades autoinmunes y/o rechazo de transplantes |
| ES2259552B1 (es) * | 2005-03-17 | 2007-06-16 | Proyecto De Biomedicina Cima, S.L. | Empleo de 5'-metiltioadenosina (mta) en la prevencion y/o tratamiento de enfermedades autoinmunes y/o rechazo de transplantes. |
| DE102010027595A1 (de) * | 2010-07-23 | 2012-01-26 | Helmut Vorbrüggen | Vermeidung von Ischämie- oder Degenerations-Schäden im Gehirn bei Anwendung von Adenosin-Derivaten |
| DE102011005232A1 (de) * | 2011-03-08 | 2012-09-13 | AristoCon GmbH & Co. KG | Adenosin und seine Derivate zur Verwendung in der Schmerztherapie |
| WO2014163152A1 (ja) * | 2013-04-05 | 2014-10-09 | ライオン株式会社 | ノンレム睡眠促進剤、深睡眠促進剤および自然睡眠誘発剤 |
| KR102245628B1 (ko) * | 2013-04-05 | 2021-04-28 | 라이온 가부시키가이샤 | 내복 조성물 |
| CN105102609B (zh) * | 2013-04-05 | 2018-07-20 | 狮王株式会社 | 酵母培养物和内服组合物 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1259341B (de) * | 1962-12-22 | 1968-01-25 | Boehringer & Soehne Gmbh | Verfahren zur Herstellung neuer 5'-Sulfoxyde von Nucleosiden |
| DE1545645A1 (de) * | 1965-12-06 | 1969-08-21 | Boehringer Mannheim Gmbh | Verfahren zur Herstellung von disubstituierten Adenosin-Derivaten |
| GB1436509A (en) * | 1973-11-27 | 1976-05-19 | Ajinomoto Kk | Method for producing s-adenosylmethionine or methylthioadenosine from yeast |
| FR2313937A1 (fr) * | 1975-06-09 | 1977-01-07 | Anvar | Medicament a base de 5' thioethers de l'adenosine |
| FR2424027A1 (fr) * | 1978-04-28 | 1979-11-23 | Merieux Inst | Nouveau medicament, notamment sedatif et inducteur de sommeil et compositions pharmaceutiques la renfermant |
-
1980
- 1980-04-22 IT IT21550/80A patent/IT1193529B/it active
-
1981
- 1981-04-17 BE BE0/204529A patent/BE888472A/fr not_active IP Right Cessation
- 1981-04-21 CA CA000375784A patent/CA1198105A/en not_active Expired
- 1981-04-21 AR AR285020A patent/AR231144A1/es active
- 1981-04-21 SE SE8102489A patent/SE460198B/sv not_active IP Right Cessation
- 1981-04-21 JP JP5930181A patent/JPS56166117A/ja active Granted
- 1981-04-21 NO NO811346A patent/NO150515C/no unknown
- 1981-04-21 DK DK176481A patent/DK159453C/da not_active IP Right Cessation
- 1981-04-21 ES ES501539A patent/ES501539A0/es active Granted
- 1981-04-21 LU LU83307A patent/LU83307A1/fr unknown
- 1981-04-22 CH CH4716/84A patent/CH650514A5/de not_active IP Right Cessation
- 1981-04-22 DE DE19813116067 patent/DE3116067A1/de active Granted
- 1981-04-22 NL NL8101984A patent/NL192111C/nl not_active IP Right Cessation
- 1981-04-22 FI FI811249A patent/FI70227C/fi not_active IP Right Cessation
- 1981-04-22 GB GB8112428A patent/GB2074446B/en not_active Expired
- 1981-04-22 FR FR8107992A patent/FR2491761A1/fr active Granted
- 1981-04-22 CH CH263281A patent/CH645544A5/de not_active IP Right Cessation
-
1982
- 1982-04-01 ES ES511039A patent/ES8306378A1/es not_active Expired
-
1983
- 1983-08-15 GB GB08321947A patent/GB2144409B/en not_active Expired
-
1984
- 1984-05-25 GB GB08413454A patent/GB2144038B/en not_active Expired
-
1987
- 1987-03-04 SE SE8700913A patent/SE466238B/sv not_active IP Right Cessation
- 1987-03-04 SE SE8700914A patent/SE464635B/sv not_active IP Right Cessation
-
1989
- 1989-02-02 JP JP1022771A patent/JPH01301692A/ja active Granted
-
1992
- 1992-06-26 MX MX9203630A patent/MX9203630A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69621756T2 (de) | Betahydroxybuttersäure oder Acetoessigsäure oder deren Salze oder Ester zur Verwendung zur Verbesserung der Gehirnfunktion | |
| DE69317494T2 (de) | Zusammensetzungen, die mono oder polyhydroxylierte Aminosäuren zur Behandlung des Insulinunabhängigen Diabetes Mellitus enthalten | |
| DE2728685A1 (de) | Arzneimittel | |
| DE69425826T2 (de) | Medikament zum schutz vor neurologischen schäden | |
| DE2329821A1 (de) | Cysteinderivate enthaltende arzneimittel | |
| CH650514A5 (de) | Verfahren zur herstellung von 5'-desoxy-5'-methylthioadenosin. | |
| EP0374096B1 (de) | 2',3'-Dideoxypurinnucleosid/Purinnucleosid-Phosphorylase-Inhibitor Kombinationstherapie und Zusammensetzungen dafür | |
| DE2166355C2 (de) | Verwendung von d,1-Sobrerol bei der Balsamtherapie der Atemwege | |
| CH621333A5 (enrdf_load_stackoverflow) | ||
| DE69003670T2 (de) | Nicht einspritzbares karzinostatisches mittel zur vorbeugung der entzündung durch 5-fluoruracil und verfahren zur behandlung von krebs. | |
| DE3873210T2 (de) | Verwendung von benzylpyridin-derivaten zur herstellung eines arzneimittels zur behandlung der demenz. | |
| EP0132595B1 (de) | Tokolytisches Mittel | |
| DE3141970C2 (enrdf_load_stackoverflow) | ||
| DE3425466A1 (de) | Synergistisches arzneimittelpraeparat zur behandlung von leberkrankheiten | |
| DE3805990C2 (enrdf_load_stackoverflow) | ||
| DE3116029A1 (de) | 3-deazaadenosin als entzuendungshemmendes mittel | |
| DE69307894T2 (de) | Ng-monomethyl-l-arginin-hydrochlorid-derivate und verfahren zu deren herstellung | |
| DE3048154C2 (enrdf_load_stackoverflow) | ||
| DE2131679A1 (de) | 3,4,5-Trimethoxybenzamidocarbonsaeure und ihre Salze sowie Arzneipraeparate | |
| DE3008335C2 (de) | 1-Aminoadamantan-D,L-2-acetamido-3-phenylpropionat, Verfahren zu seiner Herstellung und dieses Salz enthaltende pharmazeutische Zubereitungen | |
| DE1543733C3 (de) | Aluminium-bis-alpha-(p-chlorphenoxy) isobutyrat und diese Verbindung als Wirkstoff enthaltende Hellmittel | |
| DE2501649C3 (de) | Thiophen-2-carbonsäuresalz des Papaverins, Verfahren zu seiner Herstellung und diese Verbindungen enthaltende Arzneimittel | |
| DE2161588A1 (de) | Mittel zur behandlung von hyperlipoproteinaemien und verfahren zu seiner herstellung | |
| CH668361A5 (de) | Pharmazeutische zusammensetzung, verfahren zu deren herstellung und verwendung von salzen und estern der peroxydiphosphorsaeure. | |
| DE2530941C2 (de) | Verfahren zur Gewinnung von kristallinem Aescin und zur Herstellung von bestimmten Aescin-Salzen sowie Triethanolammoniumaescinat und dieses Salz enthaltende Arzneimittel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PFA | Name/firm changed |
Owner name: BIORESEARCH S.P.A. |
|
| PL | Patent ceased |